Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Lenalidomide in Relapsed/Refractory DLBCL Subtypes
NCT03212807Phase 2Withdrawn
- Sponsor
- Singapore General Hospital
- Start
- Aug 2017
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in diffuse large B-cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), primary testicular lymphoma (PTL), sponsored by Singapore General Hospital. Planned start Aug 2017; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary central nervous system lymphoma (PCNSL)primary testicular lymphoma (PTL)
Beyond the preview
Go deeper on NCT03212807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212807.